Home • Search • Translate
From Wikipedia, the free encyclopedia
Dazopride
Clinical data
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • 4-amino-5-chloro-N-(1,2-diethylpyrazolidin-4-yl)-2-methoxybenzamide
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC15H23ClN4O2
Molar mass326.83 g·mol−1

Dazopride (AHR-5531) is an antiemetic and gastroprokinetic agent of the benzamide class which was never marketed. [1] [2] [3] [4] [5] It acts as a 5-HT3 receptor antagonist and 5-HT4 receptor agonist. [3] [4] [6] In addition to its gastrointestinal effects, dazopride facilitates learning and memory in mice. [7]

See also

References

  1. ^ Grant SC, Kris MG, Gralla RJ, Clark RA, Tyson LB (1993). "Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy". Cancer Chemotherapy and Pharmacology. 31 (6): 442–444. doi: 10.1007/bf00685032. PMID  8453682. S2CID  23122385.
  2. ^ Alphin RS, Proakis AG, Leonard CA, Smith WL, Dannenburg WN, Kinnier WJ, et al. (May 1986). "Antagonism of cisplatin-induced emesis by metoclopramide and dazopride through enhancement of gastric motility". Digestive Diseases and Sciences. 31 (5): 524–529. doi: 10.1007/bf01320319. PMID  3698769. S2CID  6571531.
  3. ^ a b Costall B, Domeney AM, Gunning SJ, Kelly ME, Naylor RJ, Nohria V, et al. (July 1987). "The action of dazopride to enhance gastric emptying and block emesis". Neuropharmacology. 26 (7A): 669–677. doi: 10.1016/0028-3908(87)90227-9. PMID  3114664. S2CID  25143512.
  4. ^ a b Costall B, Domeney AM, Naylor RJ, Tattersall FD (September 1987). "Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs". Neuropharmacology. 26 (9): 1321–1326. doi: 10.1016/0028-3908(87)90094-3. PMID  2890117. S2CID  24621209.
  5. ^ Ganellin CR, Triggle DJ (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN  0-412-46630-9.
  6. ^ Villalón CM, den Boer MO, Heiligers JP, Saxena PR (January 1991). "Further characterization, by use of tryptamine and benzamide derivatives, of the putative 5-HT4 receptor mediating tachycardia in the pig". British Journal of Pharmacology. 102 (1): 107–112. doi: 10.1111/j.1476-5381.1991.tb12140.x. PMC  1917868. PMID  2043916.
  7. ^ Montgomery SA, Halbreich U (2000). Pharmacotherapy for mood, anxiety, and cognitive disorders. Washington, DC: American Psychiatric Press. ISBN  0-88048-885-9.
Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

Retrieved from " https://en.wikipedia.org/?title=Dazopride&oldid=1194454182"
From Wikipedia, the free encyclopedia
Dazopride
Clinical data
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • 4-amino-5-chloro-N-(1,2-diethylpyrazolidin-4-yl)-2-methoxybenzamide
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC15H23ClN4O2
Molar mass326.83 g·mol−1

Dazopride (AHR-5531) is an antiemetic and gastroprokinetic agent of the benzamide class which was never marketed. [1] [2] [3] [4] [5] It acts as a 5-HT3 receptor antagonist and 5-HT4 receptor agonist. [3] [4] [6] In addition to its gastrointestinal effects, dazopride facilitates learning and memory in mice. [7]

See also

References

  1. ^ Grant SC, Kris MG, Gralla RJ, Clark RA, Tyson LB (1993). "Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy". Cancer Chemotherapy and Pharmacology. 31 (6): 442–444. doi: 10.1007/bf00685032. PMID  8453682. S2CID  23122385.
  2. ^ Alphin RS, Proakis AG, Leonard CA, Smith WL, Dannenburg WN, Kinnier WJ, et al. (May 1986). "Antagonism of cisplatin-induced emesis by metoclopramide and dazopride through enhancement of gastric motility". Digestive Diseases and Sciences. 31 (5): 524–529. doi: 10.1007/bf01320319. PMID  3698769. S2CID  6571531.
  3. ^ a b Costall B, Domeney AM, Gunning SJ, Kelly ME, Naylor RJ, Nohria V, et al. (July 1987). "The action of dazopride to enhance gastric emptying and block emesis". Neuropharmacology. 26 (7A): 669–677. doi: 10.1016/0028-3908(87)90227-9. PMID  3114664. S2CID  25143512.
  4. ^ a b Costall B, Domeney AM, Naylor RJ, Tattersall FD (September 1987). "Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs". Neuropharmacology. 26 (9): 1321–1326. doi: 10.1016/0028-3908(87)90094-3. PMID  2890117. S2CID  24621209.
  5. ^ Ganellin CR, Triggle DJ (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN  0-412-46630-9.
  6. ^ Villalón CM, den Boer MO, Heiligers JP, Saxena PR (January 1991). "Further characterization, by use of tryptamine and benzamide derivatives, of the putative 5-HT4 receptor mediating tachycardia in the pig". British Journal of Pharmacology. 102 (1): 107–112. doi: 10.1111/j.1476-5381.1991.tb12140.x. PMC  1917868. PMID  2043916.
  7. ^ Montgomery SA, Halbreich U (2000). Pharmacotherapy for mood, anxiety, and cognitive disorders. Washington, DC: American Psychiatric Press. ISBN  0-88048-885-9.
Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

Retrieved from " https://en.wikipedia.org/?title=Dazopride&oldid=1194454182"

Videos

Youtube | Vimeo | Bing

Websites

Google | Yahoo | Bing

Encyclopedia

Google | Yahoo | Bing

Facebook




Top Of Page

Home • Search • Translate

© CSE